ArticleBMC microbiology2025
L-asparaginase from the novel Fusarium falciforme AUMC 16563: extraction, purification, characterization, and cytotoxic effects on PC-3, HePG-2, HCT-116, and MCF-7 cell lines.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Novel glutaminase-free l-asparaginase fromRSC advances · 2026Article
- Improved Extracellular Level of L-Asparaginase in Shaken Cultures of Escherichia coli ATCC 11,303 Using a Statistical Design Approach.Applied biochemistry and biotechnology · 2026Article
- Fungal L-Asparaginase from environmental isolates with antimicrobial and antibiofilm activities.AMB Express · 2026Article
- L-asparaginase: a review of microbial production and protein engineering with translational applications for oncology and food safety.World journal of microbiology & biotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundL-asparaginase has been a widely employed as antitumor enzyme for the treatment of acute lymphoblastic leukemia for almost three decades. The enzyme takes advantage of the inability of tumor cells to synthesize the L-asparagine and is killed by L-asparagine deprivation. Despite the availability of bacterial sources for L-asparaginase, there is a growing interest in identifying new microbial sources with improved therapeutic properties. Therefore, this study aims to investigate the production of L-asparaginase from a fungal source, to explore its potential as a novel alternative enzyme for cancer treatment.
resultsFusarium falciforme AUMC 16563 was used to produce L-asparaginase (123.42 U/mL) after 5 days, 0.2% glucose and 1.0% asparagine; were used at 25 ˚C and pH 8.0. Employing two columns of chromatography (DEAE-cellulose and Sephacryl S 200 HR), the enzyme was purified 14.26-fold, reaching a maximum activity of 5109.4 U/mg. SDS-PAGE revealed a 46.06 kDa asparaginase. The K
conclusionsThe results of the present study revealed a potent L-ASNase from endophytic F. falciforme isolated from Trifolium alexandrinum, which performs well under a variety of environmental circumstances and can be used in a number of commercial applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.